[Paper] ACHIEVE-1 glycaemic data vs the injectables
ACHIEVE-1 glycaemic data vs the injectables, which sounds obvious until you try to state the evidence for it. Spent an evening reading about small-molecule agonism at a peptide receptor. Genuinely interesting engineering. Why "oral" is doing two completely different jobs in the sentences people write here. Oral…
daily dosing changes adherence in both directions
Went looking for independent testing on this and found essentially nothing, which was clarifying.
a non-peptide agonist does not degrade the way a peptide does
What analytical method was used — this is not the usual peptide assay question?
What analytical method was used — this is not the usual peptide assay question?
Adding the standing caveat — unapproved, and research material is not for human use.
Disagree. You are comparing doses across a small molecule and a peptide, which is not a comparison of anything.
Correcting myself: that was a phase 2 readout and I described it as phase 3.
identity testing on a small molecule is a different analytical problem